NanoValent Pharmaceuticals Awarded NIH SBIR Grants Totaling ~$4...

NanoValent Pharmaceuticals, Inc., (NanoValent) a development-stage pharmaceutical company advancing targeted antibody-drug conjugate (ADC) like, lipid based therapeutics, today announced the National...(PRWeb October 01, 2018)Read the full story at https://www.prweb.com/releases/nanovalent_pharmaceuticals_awarded_nih_sbir_grants_totaling_4_million/prweb15774427.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news
More News: Grants | Nanotechnology